



POWERHOUSE ALZHEIMER'S ADVISORY BOARD TO DRIVE XANAMEM™ DEVELOPMENT

- **World leading experts in early Alzheimer's and Mild Cognitive Impairment (MCI) diagnosis and treatment join Xanamem™ Advisory Board**
- **Xanamem™'s novel mechanism of action setting it apart from other Alzheimer's treatments through blocking the production of cortisol, has attracted a powerhouse Advisory Board.**
- **Advisory Board to help design the optimum Phase II efficacy trial for Xanamem™ in Alzheimer's and MCI patients**
- **Phase II study to start in early 2016 and expected to be run in the USA (under a Food and Drug Administration (FDA) approved Investigational New Drug (IND)), ANZ and the EU**

Sydney, 17 March 2015: Actinogen Limited (Actinogen Medical, ASX: ACW), is delighted to announce the appointment of a powerhouse team of globally recognised leaders in Alzheimer's disease research to its Xanamem™ Advisory Board - **Professor Craig Ritchie** from Edinburgh UK, **Professor Colin Masters** from Melbourne Australia and **Professor Jeff Cummings** from the Cleveland Clinic USA. This Advisory Board has particular expertise in the early diagnosis and treatment of Alzheimer's disease and will help Actinogen Medical shape and drive the development of its new lead research drug, Xanamem™.

Xanamem™ is a new promising treatment for early Alzheimer's disease and its precursor stage, Mild Cognitive Impairment. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease. Thomson Reuters recently rated Xanamem™ in the top five drugs in Phase I development globally.

The first major priority for the Advisory Board will be to assist Actinogen Medical in designing the optimum Phase II study to best demonstrate the efficacy and safety of Xanamem™ in patients with Mild Cognitive Impairment and Alzheimer's disease. Actinogen Medical expects to start this study in early 2016 and for it to run in Australia/New Zealand, Europe and the USA, under an FDA approved IND. The broad geographic spread of the members of the Xanamem™ Advisory Board will provide a true global dimension to Actinogen Medical's research strategy for Xanamem™.

The Advisory Board will be chaired by **Professor Craig Ritchie**, Professor of Psychiatry of Ageing at the University of Edinburgh. Professor Ritchie is a leading authority on clinical trials in dementia and has been senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition. He has extensive knowledge of the industry, having sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organizations with an interest in developing drugs and trials infrastructure for Alzheimer's disease. Professor Ritchie is also leading the PREVENT project, a major Scottish initiative to identify mid-life risks for dementia and the EPAD (European Prevention of Alzheimer's Dementia) consortium to better understand early aspects of Alzheimer's disease before dementia develops. He has published extensively on the topics of dementia and delirium.


Professor Colin Masters is currently the Executive Director of the Mental Health Research Institute, and a Laureate Professor at the University of Melbourne. He is also the Senior Deputy Director of the Florey Institute of Neuroscience and Mental Health, and a consultant at the Royal Melbourne Hospital. He has focused his career on research in Alzheimer's disease and other neurodegenerative diseases. With over 35 years' experience, he is widely acknowledged as having had a major worldwide influence on Alzheimer's disease research and the causes of the disease. More recently, his focus has been on describing the natural history of Alzheimer's disease as a necessary preparatory step for therapeutic disease modification. Prof. Masters is also a driving force behind the AIBL (Australian Imaging, Biomarkers & Lifestyle) study to determine which biomarkers, cognitive characteristics, and health and lifestyle factors determine subsequent development of Alzheimer's.

Professor Jeff Cummings is the Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is a world-renowned Alzheimer's researcher and leader of clinical trials and has been recognized for his research and leadership contributions in the field of Alzheimer's disease through the Henderson Award of the American Geriatrics Society (2006), the Research Award of the John Douglas French Alzheimer's Research Foundation (2008), and the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association (2008). In 2010, he was honoured by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award.

Professor Cummings has a strong interest in clinical trials, developing new therapies for brain diseases and the interface of neuroscience and society. He is a past president of the Behavioural Neurology Society and of the American Neuropsychiatric Association and has authored or edited 39 books and published over 650 peer-reviewed papers.

Actinogen Medical CEO, Bill Ketelbey said: "The exceptional quality of this Advisory Board will put Xanamem™ clinical research at the forefront of early Alzheimer's and Mild Cognitive Impairment diagnosis and treatment. It not only speaks to the strength of the science, but it is also a real coup to have secured experts of such high global standing in Alzheimer's and MCI research to support the development of Xanamem™. Actinogen Medical and Xanamem™ will have access to the Board's significant collective intellect and research experience that are at the core of initiatives like EPAD and AIBL. This will be a huge asset to driving the future research and development of Xanamem™."

ENDS

Dr. Bill Ketelbey
CEO & Managing Director
Actinogen Medical
T: +61 (0) 2 8964 7401
E: Bill.ketelbey@actinogen.com.au
 @billketelbey

About Actinogen Medical

Actinogen Medical is an Australian biotechnology company focused on the treatment of Alzheimer's disease and Mild Cognitive Impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat Alzheimer's disease and other age-related neurodegenerative diseases. The lead candidate Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer's. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results expected in mid-2015. Actinogen Medical plans to initiate a Phase II study in Alzheimer's and Mild Cognitive Impairment in 2016.

About Xanamem™

Xanamem™ is under development as a potential new therapy for Alzheimer's disease and Mild Cognitive Impairment, conditions with a multi-billion dollar market potential. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.